Medtech stories we missed this week: Nov. 17, 2017

From Skyline Medical’s joint venture to Lensar receiving FDA clearance and CE Mark, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Skyline Medical launches JV deal with Helomics Skyline Medical announced in a Nov. 15 press release that it has signed a joint venture agreement with Helomics.

GE to refocus on healthcare, other select divisions

GE  (NYSE:GE) said this week it aims to narrow its business focus to healthcare, power and aviation, according to a Reuters report. The move comes as part of a maneuver the company hopes will center it behind the businesses with the most growth potential. GE will also focus on sectors where it has innovative technology, appropriate […]

FDA approves first pill with sensor to track ingestion

The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an […]

Avinger slashes jobs, Q3 sales down 61%

Avinger (Nasdaq:AVGR) – maker of the Lumivascular image-guided, catheter-based system to treat peripheral artery disease (PAD) – continued to experience declining sales as it retrenched during the third quarter, according to its newest earnings report. The Redwood, Calif.–based company has been cutting jobs and other costs – and focusing on existing accounts and winning FDA clearance

Medtronic is closer to VenaSeal coverage: Here’s how

Medtronic is touting its new CPT codes for the VenaSeal varicose vein closure device – codes that company officials think bring the device closer to positive coverage from public and private insurers in the U.S. CMS announced the new codes on Nov. 1 as part of final rules for the 2018 Medicare Physician Fee Schedule (CMS-1676-F)

Haemonetics to cut 11% of workforce

Haemonetics (NYSE:HAE) said today that it plans to cut roughly 11% of its global workforce as it looks to pare $80 million from its annual cash burn by the end of fiscal 2020. The Braintree, Mass.-based blood management company said it plans to eliminate 350 positions by the end of its fiscal year in April. The company reported […]

Avinger inks $15m share purchase deal

Avinger (NSDQ:AVGR) said today it inked a $15 million stock purchase agreement with Lincoln Park Capital Fund. Through the deal, the Redwood City, Calif.–based company said it will have the right and sole discretion to sell $15 million worth of shares over a 30-month period to Lincoln Park Capital, with proceeds slated to support working capital

7 medtech stories we missed this week: Nov. 3, 2017

From Hologic’s new product launch to CapsoVision gettting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Hologic launches new MyoSure device Hologic announced in a Nov. 1 press release that it has launched its MyoSure Manual Device in the U.S. The device is designed

Integer posts street-beating Q3

Integer today posted third quarter earnings that beat expectations on Wall Street. The Frisco, Texas-based company posted profits of $13.7 million, of 43¢ per share, on sales of $363.3 million for the 3 months ended September 29, seeing bottom-line growth of 19.5% while sales grew 4.8% compared to the same period last year. Adjusted to

Flex posts Q2 FY2018 earnings beat

Flex today posted second quarter 2018 earnings results that met expectations on Wall Street. The San Jose, Calif.-based company posted profits of $205.1 million, or 38¢ per share, on sales of $6.3 billion for the 3 months ended September 30, seeing the bottom line swing from $2.5 million in the red while sales grew 4.4%

Icon shares rise on Q3 beat-and-raise

Shares in Icon rose today after the company beat expectations on Wall Street with its third quarter earnings results. The Dublin, Ireland-based company posted profits of $74.2 million, or $1.35 per share, on sales of $440.3 million for the 3 months ended September 30, seeing bottom-line growth of 10% while sales grew 4.8% compared with

Proto Labs gains on Q3 sales, earnings beats

Shares in Proto Labs (NSDQ:PRLB) are up today after the contract manufacturer beat the consensus forecast on Wall Street for its third-quarter sales and earnings. Maple Plain, Minn.-based Proto Labs posted profits of $13.2 million, or 49¢ per share, on sales of $88.1 million for the three months ended Sept. 30, for a bottom-line gain

DSM Biomedical and Cerapedics partner for peptide enhanced bone graft

DSM Biomedical has partnered with Cerapedics to create and manufacture the next generation of peptide-enhanced bone graft. The partnerships allows for DSM’s regenerative materials capabilities to be used with Cerapedics’s proprietary synthetic small peptide (P-15) technology. Designed for fast and predictable remodeling in bone graft substitute applications, DSM’s newest bioceramic platform is make of a

Less than half of healthcare professionals think medtech brands meet needs

Roughly two-fifths of healthcare professionals say medical device brands aren’t meeting expectations, and failure to offer flexible contract options is also a problem, according to a new survey from Vennli (South Bend, Ind.). The survey, called “Differentiating to Win in Medical Device Marketing,” polled over 9,000 physicians, dentists and other clinicians to figure out what

Gerresheimer expects revenue recovery after lackluster third quarter

Gerresheimer AG expects to have a recovery in revenues for its fourth quarter after having lackluster numbers in the third quarter. The company raked in 331.5M Euros in its third quarter, which is 5.4% less than the year prior. The company suggests that the decrease in revenue it partly due to a lower demand doe